SATB1 and 2 in colorectal cancer

Carcinogenesis

Volumn 36, Issue 2, 2014, Pages 186-191

  Brocato, Jason ^a   Costa, Max ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 182; MICRORNA 31; NUCLEAR MATRIX PROTEIN; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 1; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 2; TUMOR MARKER; UNCLASSIFIED DRUG; MATRIX ATTACHMENT REGION BINDING PROTEIN; MICRORNA; MIRN182 MICRORNA, HUMAN; MIRN31 MICRORNA, HUMAN; SATB1 PROTEIN, HUMAN; SATB2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; FALSE POSITIVE RESULT; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION; BIOSYNTHESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS;

CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX ATTACHMENT REGION BINDING PROTEINS; MICRORNAS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84928186890     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu322     Document Type: Review

References (82)

1. Britanova, O. et al. (2005) Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS. Eur. J. Neurosci., 21, 658-668.
2. Dobreva, G. et al. (2006) SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell, 125, 971-986.
3. FitzPatrick, D.R. et al. (2003) Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum. Mol. Genet., 12, 2491-2501.
4. Alcamo, E.A. et al. (2008) Satb2 regulates callosal projection neuron identity in the developing cerebral cortex. Neuron, 57, 364-377.
5. Conner, J.R. et al. (2013) SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology, 63, 36-49.
6. Gyorgy, A.B. et al. (2008) SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons. Eur. J. Neurosci., 27, 865-873.
7. Sheehan-Rooney, K. et al. (2010) A cross-species analysis of Satb2 expression suggests deep conservation across vertebrate lineages. Dev. Dyn., 239, 3481-3491.
8. Savarese, F. et al. (2009) Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression. Genes Dev., 23, 2625-2638.
9. Tashiro, K. et al. (2011) A mammalian conserved element derived from SINE displays enhancer properties recapitulating Satb2 expression in early-born callosal projection neurons. PLoS One, 6, e28497.
10. Yang, M.H. et al. (2013) Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS One, 8, e85353.
11. Yang, M.H. et al. (2014) microRNA-182 targets special AT-rich sequencebinding protein 2 to promote colorectal cancer proliferation and metastasis. J. Transl. Med., 12, 109.
12. Hassan, M.Q. et al. A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc. Natl. Acad. Sci. U. S. A., 107, 19879-19884.
13. Deng, Y. et al. (2013) Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev., 22, 2278-2286.
14. Dobreva, G. et al. (2003) SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev., 17, 3048-3061.
15. Ito, M. et al. (2014) MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. Int. J. Cancer.
16. Kohwi-Shigematsu, T. et al. (2013) Genome organizing function of SATB1 in tumor progression. Semin. Cancer Biol., 23, 72-79.
17. Mir, R. et al. (2012) Chromatin organizer SATB1 as a novel molecular target for cancer therapy. Curr. Drug Targets, 13, 1603-1615.
18. Nodin, B. et al. (2012) Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn. Pathol., 7, 115.
19. Dickinson, L.A. et al. (1992) A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell, 70, 631-645.
20. Yasui, D. et al. (2002) SATB1 targets chromatin remodelling to regulate genes over long distances. Nature, 419, 641-645.
21. Gattinoni, L. et al. (2010) Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin. Cancer Res., 16, 4695-4701.
22. Notani, D. et al. (2010) Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol., 8, e1000296.
23. Zheng, J. (2008) Is SATB1 a master regulator in breast cancer growth and metastasis? Womens. Health (Lond. Engl)., 4, 329-332.
24. Elebro, J. et al. (2014) Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. J. Transl. Med., 12, 289.
25. Deng, Y.F. et al. (2014) Aberrant SATB1 expression is associated with Epstein-Barr virus infection, metastasis and survival in human nasopharyngeal cells and endemic nasopharyngeal carcinoma. Int. J. Clin. Exp. Pathol., 7, 2454-2461.
26. Han, B. et al. (2013) Expression and biological roles of SATB1 in human bladder cancer. Tumour Biol., 34, 2943-2949.
27. Mao, L. et al. (2013) SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J. Transl. Med., 11, 111.
28. Selinger, C.I. et al. (2011) Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J. Thorac. Oncol., 6, 1179-1189.
29. Xiang, J. et al. (2012) AT-rich sequence binding protein 1: contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol. Lett., 3, 865-870.
30. Tu, W. et al. (2012) Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int., 32, 1064-1078.
31. Chu, S.H. et al. (2012) Upregulation of SATB1 is associated with the development and progression of glioma. J. Transl. Med., 10, 149.
32. Agrelo, R. et al. (2009) SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev. Cell, 16, 507-516.
33. Cheng, C. et al. (2014) Overexpression of SATB1 is associated with biologic behavior in human renal cell carcinoma. PLoS One, 9, e97406.
34. Zhang, Y. et al. (2014) Expression of SATB1 promotes the growth and metastasis of colorectal cancer. PLoS One, 9, e100413.
35. Fang, X.F. et al. (2013) Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J. Gastroenterol., 19, 2331-2339.
36. Niu, Y. et al. (2014) Increased expressions of SATB1 and S100A4 are associated with poor prognosis in human colorectal carcinoma. APMIS.
37. McInnes, N. et al. (2012) FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene, 31, 1045-1054.
38. Patani, N. et al. (2009) The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int., 9, 18.
39. Endo, K. et al. (2013) Upregulation of special AT-rich-binding protein 1 by Epstein-Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer. J. Gen. Virol., 94(Pt 3), 507-513.
40. Shen, Z. et al. (2013) Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression. J. Transl. Med., 11, 217.
41. Ye, C.S. et al. (2014) Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma. Int. J. Clin. Exp. Pathol., 7, 914-922.
42. Liu, C.X. et al. (2010) Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao, 30, 1389-1391, 1394.
43. Shukla, S. et al. (2013) Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. PLoS One, 8, e53527.
44. Huang, B. et al. (2013) Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int., 13, 8.
45. Nodin, B. et al. (2012) Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J. Ovarian Res., 5, 24.
46. Zhao, X.L. et al. (2011) Expression of SATB1 and BRMS1 in ovarian serous adenocarcinoma and its relationship with clinieopathological features. Sichuan Da Xue Xue Bao Yi Xue Ban, 42, 82-85, 105.
47. Li, G. et al. (2012) Expression of SATB1 in hepatocellular carcinoma cell lines with different invasive capacities. Nan Fang Yi Ke Da Xue Xue Bao, 32, 986-990, 994.
48. Peng, Z.K. et al. (2011) Expression of special AT-rich sequence-binding protein 1 mRNA in hepatocellular carcinoma and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao, 31, 1207-1211.
49. Chu, S.H. et al. (2013) Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme. Mol. Med. Rep., 7, 139-143.
50. Wang, Y. et al. (2014) SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. Blood, 123, 3452-3461.
51. Han, H.J. et al. (2008) SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature, 452, 187-193.
52. Wang, S. et al. (2009) Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J. Pathol., 219, 114-122.
53. Liu, T.R. et al. (2012) Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. PLoS One, 7, e40704.
54. Seong, B.K. et al. (2014) SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization. Oncogene.
55. Magnusson, K. et al. (2011) SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am. J. Surg. Pathol., 35, 937-948.
56. Eberhard, J. et al. (2012) A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br. J. Cancer, 106, 931-938.
57. Schee, K. et al. (2012) Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer, 12, 505.
58. Chung, J. et al. (2010) SATB2 augments ΔNp63α in head and neck squamous cell carcinoma. EMBO Rep, 11, 777-783.
59. Patel, S.G. et al. (2012) Familial colon cancer syndromes: an update of a rapidly evolving field. Curr. Gastroenterol. Rep., 14, 428-438.
60. Toiyama, Y. et al. (2014) DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem. Biophys. Res. Commun, 1-2, 44-57.
61. Lin, F. et al. (2014) Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Arch. Pathol. Lab. Med., 138, 1015-1026.
62. Clancy, H.A. et al. (2012) Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer. Metallomics, 4, 784-793.
63. Hong, Y.S. et al. (2014) Health effects of chronic arsenic exposure. J. Prev. Med. Public Health, 47, 245-252.
64. Sun, H. et al. (2011) Comparison of gene expression profiles in chromate transformed BEAS-2B cells. PLoS One, 6, e17982.
65. Zhang, J. et al. (2013) SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PLoS One, 8, e47902.
66. Al-Sohaily, S. et al. (2014) Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. Histopathology, 65, 155-163.
67. Wang, Q. et al. (2012) Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis. Oncol. Rep., 28, 2029-2034.
68. Cekaite, L. et al. (2012) MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia, 14, 868-879.
69. Liu, H. et al. (2013) Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int. J. Colorectal Dis., 28, 697-703.
70. Ma, Q. et al. (2011) Differential expression of colon cancer micro-RNA in microarry study. Sichuan Da Xue Xue Bao. Yi Xue Ban, 42, 344-348.
71. Liu, C.J. et al. (2010) miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res., 70, 1635-1644.
72. Wong, Q.W. et al. (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology, 135, 257-269.
73. Wong, T.S. et al. (2008) Mature miR-184 as potential oncogenic micro-RNA of squamous cell carcinoma of tongue. Clin. Cancer Res., 14, 2588-2592.
74. Liu, X. et al. (2010) MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest., 120, 1298-1309.
75. Liu, Z. et al. (2012) MiR-182 overexpression in tumourigenesis of highgrade serous ovarian carcinoma. J. Pathol., 228, 204-215.
76. Wszolek, M.F. et al. (2011) A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol. Oncol., 29, 794. e1-801.e1.
77. Schaefer, A. et al. (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer, 126, 1166-1176.
78. Valastyan, S. et al. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137, 1032-1046.
79. Moskwa, P. et al. (2011) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell, 41, 210-220.
80. Sun, Y. et al. (2010) Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem. Biophys. Res. Commun., 396, 501-507.
81. Lynam-Lennon, N. et al. (2012) MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J. Mol. Med. (Berl)., 90, 1449-1458.
82. Krishnan, K. et al. (2013) MicroRNA-182-5p targets a network of genes involved in DNA repair. RNA, 19, 230-242.